Get the Stockscreener App
3.94
2.72%
-0.11
After Hours:
3.86
-0.08
-2.03%
Atossa Therapeutics Inc stock is traded at $3.94, with a volume of 244.70K.
It is down -2.72% in the last 24 hours and down -59.83% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$4.05
Open:
$4.05
24h Volume:
244.70K
Relative Volume:
2.00
Market Cap:
$33.93M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-17.91
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
-26.08%
1M Performance:
-59.83%
6M Performance:
-66.01%
1Y Performance:
-65.83%
1-Day Range:
$3.76
$4.15
1-Week Range:
$3.76
$5.54
52-Week Range:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
3.94 | 34.88M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PR Newswire
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Market Outlook: Is Atossa Therapeutics Inc part of any ETFWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Mammoth Energy sets March 6 call to review full-year 2025 results - Stock Titan
Atossa Therapeutics Maintains Strong Market Position for (Z)-End - GuruFocus
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - Sahm
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Genetics (NASDAQ:ATOS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Asianet Newsable
Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year LowWhat's Next? - MarketBeat
Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens - TechStock²
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January - MarketBeat
Aug PreEarnings: How volatile is SKYQ stockWeekly Market Summary & Weekly Market Pulse Updates - baoquankhu1.vn
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd - MarketBeat
Can Atossa Therapeutics Inc. lead its sector in growthGap Up & Verified Swing Trading Watchlist - mfd.ru
Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook - simplywall.st
Risk Hedge: Can Adagene Inc. Depositary Receipt stock outperform in a bear market2025 Sector Review & Long-Term Safe Investment Plans - baoquankhu1.vn
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - PR Newswire
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (2026-01-21) - Seeking Alpha
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Big Picture: Is Atossa Therapeutics Inc part of any ETF2025 Fundamental Recap & Reliable Price Breakout Signals - baoquankhu1.vn
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z) - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program - The Globe and Mail
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving AverageHere's Why - MarketBeat
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - Улправда
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):